Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose- ranging trial

Circulation

Volumn 95, Issue 4, 1997, Pages 846-854

  Magnus Ohman, E ^a   Kleiman, Neal S ^b   Gacioch, Gerald ^d   Worley, Seth J ^e   Navetta, Frank I ^f   David Talley, J ^g   Vernon Anderson, H ^c   Ellis, Stephen G ^h   Cohen, Mark D ⁱ   Spriggs, Douglas ^j   Miller, Michael ^k   Kereiakes, Dean ^l   Yakubov, Steven ^m   Kitt, Michael M ⁿ   Sigmon, Kristina N ^a   Califf, Robert M ^a   Krucoff, Mitchell W ^a   Topol, Eric J ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d Rochester   (United States)

^e LANCASTER GENERAL HOSPITAL   (United States)

^f Mother Frances Hospital   (United States)

^g UNIVERSITY OF LOUISVILLE   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ St Francis Hospital   (United States)

^j Morton Plant Hospital   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l CHRIST HOSPITAL   (United States)

^m MidWest Cardiology Research Foundation   (United States)

ⁿ MILLENNIUM PHARMACEUTICALS INC   (United States)

more..

Author keywords

myocardial infarction; platelet aggregation inhibitors; reperfusion; thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; INTEGRIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HEART REINFARCTION; HUMAN; INCIDENCE; LUNG EDEMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT; THROMBOCYTE AGGREGATION;

EID: 16944362255     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.95.4.846     Document Type: Article

References (11)

1. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation. 1995;91:1923-1928.
2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
3. Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol. 1994;74:1220-1228.
4. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993;88:1361-1374.
5. Popma JJ, Topol EJ. Adjuncts to thrombolysis for myocardial reperfusion. Ann Intern Med. 1991;115:34-44.
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
7. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
8. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1992;19:1065-1069.
9. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Design of potent and specific integrin antagonists: peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 1993;268:1066-1073.
10. Charo IF, Scarborough RM, du Mee CP, Wolf D, Phillips DR, Swift RL. Pharmacodynamics of the GPIIb-IIIa antagonist Integrilin: phase I clinical studies in normal healthy volunteers. Circulation. 1992;86(suppl I):I-260. Abstract.
11. Harrington RA, Schulman SP, Kleiman NS, Lincoff AM, Goldschmidt-Clermont PJ, Joseph D, Sigmon KN, Parker J, Marchant K, Kitt MM. Profound, sustained, and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina. Circulation. 1994;90(suppl I):I-232. Abstract.